Trial · NCT05564052
Results by group305
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 305
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Discontinuation of Treatment Ibrutinib/Lenalidomide | 1 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Discontinuation of Treatment Ibrutinib/Lenalidomide | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Discontinuation of Treatment Ibrutinib/Lenalidomide | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Discontinuation of Treatment Ibrutinib/Lenalidomide | 2 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | Discontinuation of Treatment Rituximab | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | Discontinuation of Treatment Rituximab | 1 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | Discontinuation of Treatment Rituximab | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | Discontinuation of Treatment Rituximab | 1 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm | Monotherapy Arm: Ibrutinib 560 mg | 1 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | 7 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | 3 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | 5 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | 8 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm | Monotherapy Arm: Ibrutinib 560 mg | 1 | Participants | ||
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | 4 | Participants | ||
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B | Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2 | 3 | Participants | ||
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B | Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2 | 2 | Participants | ||
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B | Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2 | 5 | Participants | ||
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm | Monotherapy Arm: Ibrutinib 560 mg | 1 | Participants | ||
| Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Arms A1, A2, A3 and B | Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2 | aPTT Prolonged Grade 1 | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05564052/results